Crescent Biopharma Grants 129,626 Stock Options to Attract Talent

Written by Emily J. Thompson, Senior Investment Analyst

Source: Globenewswire

Updated: Dec 18 2025

0mins

CBIO+1.06%

Should l Buy CBIO?

Source: Globenewswire

Options Grant: Crescent Biopharma's Board approved the grant of 129,626 stock options to three non-executive employees as part of the 2025 Employment Inducement Incentive Award Plan, aimed at attracting key talent and enhancing team stability.
Incentive Structure: The options have an exercise price of $13.21 per share, aligning with the closing price on December 15, 2025, ensuring that employees can benefit financially as the company performs well.
Vesting Schedule: Options will vest one-fourth on the first anniversary of the employee's start date, with one-forty-eighth vesting monthly thereafter, ensuring long-term employee commitment through continuous service with Crescent.
Strategic Aim: By implementing such incentive measures, Crescent Biopharma aims to build an efficient oncology team to rapidly advance innovative therapies like its PD-1 x VEGF bispecific antibody, further solidifying its market position in the biotechnology sector.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy CBIO?" and start using high-conviction signals backed by rigorous historical data.

CBIO

$9.51+Infinity%1D

Analyst Views on CBIO

Wall Street analysts forecast CBIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CBIO is 28.20 USD with a low forecast of 22.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Analyst Rating

6 Buy

0 Hold

0 Sell

Strong Buy

Current: 9.410

Low

22.00

Averages

28.20

High

35.00

Current: 9.410

Low

22.00

Averages

28.20

High

35.00

Piper Sandler

Overweight

initiated

$35

2026-01-28

Reason

Piper Sandler

Price Target

$35

AI Analysis

2026-01-28

initiated

Overweight

Reason

Piper Sandler initiated coverage of Crescent Biopharma with an Overweight rating and $35 price target. The firm notes the company's lead asset CR-001 is a PD-1xVEGF bsAb designed to match ivonescimab's cooperativity with potential for subQ administration. A Phase 1/2 is initiating in Q1 2026 to evaluate the asset in several solid tumors. Piper models three indications based on demonstrated efficacy of PD-1xVEGF bsAb in these indications, and cumulatively models about $1.4B in risk-adjusted revenues by 2036. Moreover, the company has a pipeline of ADCs and is at the forefront of this next wave of oncology development combining PD1xVEGF with ADCs.

Guggenheim

Brad Canino

Buy

initiated

$35

2026-01-21

Reason

Guggenheim

Brad Canino

Price Target

$35

2026-01-21

initiated

Buy

Reason

Guggenheim analyst Brad Canino initiated coverage of Crescent Biopharma (CBIO) with a Buy rating and $35 price target. Crescent is 12-15 months from initial CR-001 data due in Q1 of 2027 that will include first-line lung patients to provide a clear comparable to Summit Therapeutics' (SMMT) ivonescimab and the company unveiled a proprietary ADC pipeline against two clinically validated targets that can generate independent value with monotherapy activity and be synergistic with CR-001 in earlier solid tumor treatment settings, the analyst tells investors. If the firm's Summit ivonescimab thesis plays out successfully in 2026, "like we think it will," the firm sees Crescent being set up to be "awarded significant value both from what the company is replicating and what the company is pioneering," the analyst added.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CBIO

Unlock Now

About CBIO

Crescent Biopharma, Inc. is a biotechnology company. The Company is focused on advancing the next wave of therapies for cancer patients. The Company’s pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates. The Company’s lead program is CR-001, a tetravalent PD-1 x VEGF bispecific antibody in development for the treatment of solid tumors, and it is also advancing CR-002 and CR-003, antibody drug conjugates (ADCs) with topoisomerase inhibitor payloads. CR-002 and CR-003 are ADCs designed to deliver clinically active cytotoxic drugs known as topoisomerase inhibitors to tumor cells. Each of these programs has the potential to deliver therapeutics with clinical efficacy both as a monotherapy and in combination with CR-001 with significant potential across solid tumor indications.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Crescent Biopharma to Participate in Biotech Summit 2026

3 days agoNewsfilter

Management Participation: Crescent Biopharma is scheduled to participate in the Guggenheim Emerging Outlook: Biotech Summit on February 12, 2026, in New York, showcasing its latest advancements in cancer therapies, which is expected to attract investor attention and enhance the company's visibility.
Live Webcast Availability: The event will be webcast live on the company's website, with a replay accessible for 90 days post-event, enhancing interaction with investors and increasing transparency and trust.
Pipeline Overview: Crescent Biopharma's clinical-stage pipeline includes a PD-1 x VEGF bispecific antibody and novel antibody-drug conjugates (ADCs), aiming to rapidly advance cancer treatments that could transform existing therapeutic paradigms.
Company Vision: Crescent Biopharma is committed to becoming a world-leading oncology company, leveraging multiple modalities and combination regimens to rapidly advance potentially transformative therapies for a range of solid tumors, demonstrating its strategic ambition in the biotech sector.

Analysts Bullish on Century Communities, Target Price Set at $92

Jan 21 2026Benzinga

Century Communities Rating: Analyst James McCanless initiated coverage on Century Communities Inc (NYSE:CCS) with a Market Outperform rating and a price target of $92, indicating significant upside from Tuesday's close of $66.26, reflecting confidence in the company's growth prospects.
Alumis Inc Rating: Chardan Capital analyst Janani Sundararajan initiated coverage on Alumis Inc (NASDAQ:ALMS) with a Buy rating and a price target of $37, suggesting a 41% upside from Tuesday's close of $26.06, showcasing optimism about its business outlook.
Credo Technology Rating: Rosenblatt analyst Mike Genovese initiated coverage on Credo Technology Group Holding Ltd (NASDAQ:CRDO) with a Neutral rating and a price target of $170, indicating potential upside from the current price of $153.22, reflecting a cautious view on its market performance.
Crescent Biopharma Rating: Guggenheim analyst Brad Canino initiated coverage on Crescent Biopharma Inc (NASDAQ:CBIO) with a Buy rating and a price target of $35, representing a 150% upside from Tuesday's close of $13.98, indicating strong confidence in its future growth potential.